Pfizer wins FDA approval for hemophilia B drug that will be first once-weekly treatment
The new drug would allow patients to produce the needed clotting protein for an extended period, reducing the need for ...
FDA Approves Pfizer's Second Hemophilia Drug With Six Months
Hympavzi (marstacimab-hncq) for routine prophylaxis to prevent or reduce the frequency of bleeding episodes in adults and ...
FiercePharma11d
Pfizer doubles down with its 2nd FDA hemophilia approval in 6 months
Six months after scoring FDA approval for hemophilia B gene therapy Beqvez, Pf | For the second time in six months, the FDA ...
FDA approves Hympavzi for hemophilia
The U.S. Food and Drug Administration (FDA) approved Hympavzi (marstacimab-hncq) for routine prophylaxis to prevent or reduce ...
Medscape11d
FDA Approves Pfizer's Hympavzi for Hemophilia A, B
The monoclonal antibody is the first non-factor, once-weekly treatment approved in the United States for hemophilia B.
BioPharma Dive8d
Pfizer drug for hemophilia approved by FDA
The approval of Hympavzi Friday was a dose of good news for Pfizer, which is dealing with research setbacks and a challenge from an activist investor.
FDA approves first once-weekly drug treatment regimen for hemophilia
Patients suffering from hemophilia received a "meaningful" advancement on Friday when federal regulators approved the first ...
MyChesCo on MSN7d
FDA Approves Hympavzi for Hemophilia Treatment, Offering Novel Approach to Bleeding Disorder Management
The U.S. Food and Drug Administration (FDA) has approved Hympavzi (marstacimab-hncq) for routine prophylaxis aimed at ...
The American Journal of Managed Care11d
FDA Approves Marstacimab, First Weekly Sub-Q Option for Hemophilia B
The American Journal of Managed Care provides insights into the latest news and research in managed care across multimedia ...
U.S. FDA Approves Pfizer’s HYMPAVZI™ (marstacimab-hncq) for the Treatment of Adults and Adolescents with Hemophilia A or B Without Inhibitors
Pfizer Inc. (NYSE: PFE) announced today that the U.S. Food and Drug Administration (FDA) has approved HYMPAVZIâ„¢ ...
Too Old to Operate12d
Fidanacogene elaparovovec may reduce bleeding in men with hemophilia B
In this randomized controlled trial, fidanacogene elaparovovec therapy significantly reduced the mean annualized rate of ...
Managed Healthcare Executive11d
FDA Approves Hympavzi for Hemophilia A and B
The FDA approved Pfizer’s Hympavzi (marstacimab-hncq) to prevent or reduce the frequency of bleeding episodes in patients age ...